Classical Hodgkin's Lymphoma | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Classical Hodgkin lymphoma is one of the more common lymphomas and is typically thought to be a highly curable condition with first-line chemotherapy and radiotherapy in some cases. Major issues continue to exist despite these excellent results. First, despite front-line regimens, some patients still cannot be cured, and second, many patients who have been cured of classical Hodgkin lymphoma still pass away too soon as a result of the late toxic effects of their treatment. Younger people are more likely to develop nodular sclerosis Hodgkin lymphoma than older people are to develop mixed cellularity Hodgkin lymphoma. Nodular sclerosis is present in 70% of cases of classical Hodgkin lymphoma, while 25% have mixed cellularity, 5% have lymphocyte-rich tissue, and less than 1% have lymphocyte-depleted tissue.

Description

Classical Hodgkin lymphoma is one of the more common lymphomas and is typically thought to be a highly curable condition with first-line chemotherapy and radiotherapy in some cases. Major issues continue to exist despite these excellent results. First, despite front-line regimens, some patients still cannot be cured, and second, many patients who have been cured of classical Hodgkin lymphoma still pass away too soon as a result of the late toxic effects of their treatment. Given that classical Hodgkin lymphoma patients are typically in their mid-30s, the disease has a strikingly large impact on the number of years lost to productive life. With the approval of immunotherapy primarily in relapse settings, the gold standard of chemotherapy (often combined with radiotherapy) has changed in recent years. Hodgkin lymphoma is a disease that is very treatable. Although the majority of patients respond completely to frontline therapy, there are still important clinical needs that have not been addressed, such as relapsed/refractory disease, treatment-related morbidity, diminished quality of life, and poor outcome in patients over the age of 60. These needs might be met by the application of novel therapies, such as antibody-drug conjugates and check point inhibitors, in the frontline setting, along with sequential strategies and more individualized treatment intensities.

Classical Hodgkin's Lymphoma (Epidemiology)

For every 100,000 Americans, there are 2.6 cases of Hodgkin lymphoma, according to estimates. One in ten lymphomas found in the US are caused by this condition. With a bimodal distribution peaking at age 55 and older, the majority of those affected are between the ages of 20 and 40. In pediatrics, where males are more affected than females, boys account for 85% of cases. Younger people are more likely to develop nodular sclerosis Hodgkin lymphoma than older people are to develop mixed cellularity Hodgkin lymphoma. Nodular sclerosis is present in 70% of cases of classical Hodgkin lymphoma, while 25% have mixed cellularity, 5% have lymphocyte-rich tissue, and less than 1% have lymphocyte-depleted tissue. About 5% of all cases of the illness are nodular lymphocyte-predominant Hodgkin lymphomas, or NLPHL.

Classical Hodgkin's Lymphoma -Current Market Size & Forecast Trends

The market for classical Hodgkin's lymphoma treatment was valued at approximately USD 8.98 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.3%, reaching nearly USD 15.70 billion by 2030. This growth is driven by increasing incidence rates, advancements in treatment options including chemotherapy, immunotherapy, and targeted therapies, as well as ongoing research and development efforts aimed at improving patient outcomes. The market is characterized by a robust competitive landscape with significant contributions from North America, which is expected to maintain the largest market share due to its established healthcare infrastructure and high levels of investment in oncology research. As new therapies are developed and approved, the market for classical Hodgkin's lymphoma is anticipated to continue expanding through 2035, with an estimated value likely exceeding USD 20 billion by that time.

The majority of cHL patients will recover with standard therapy. The cornerstone of frontline management in North America, regardless of stage, is doxorubicin (or adriamycin), bleomycin, vinblastine, and dacarbazine (ABVD), the gold standard of care for early stage cHL. The HD10 trial, which demonstrated that the addition of 20 Gy of involved-field radiotherapy (IFRT) to 2 cycles of ABVD is as effective as 30 Gy, tested the advantage of adding radiation therapy in the early favorable setting. As opposed to six or eight cycles of eBEACOPP in the case of PET2 negativity following two cycles of eBEACOPP, the HD18 trial showed that in advanced-stage cHL, reducing therapy to a total of four cycles of eBEACOPP was non-inferior. However, they run the risk of developing long-term issues, such as an exponential rise in cardiopulmonary toxicities, secondary malignancies, and decreased quality of life. Therefore, the most recent developments in the management of cHL have concentrated on maximizing treatment approaches to improve outcome while lowering toxicity. In more recent strategies, relapse risk and chemotherapy-related toxicity are reduced by combining novel immunotherapies like brentuximab vedotin (BV) and anti-PD-1 monoclonal antibodies (mAb). In order to prevent pulmonary toxicity, bleomycin was initially added to ABVD and later replaced with BV, an antibody-drug conjugate that targets tumor cells only when they express the CD30 antigen.

Report Highlights

Classical Hodgkin's Lymphoma - Current Market Trends

Classical Hodgkin's Lymphoma - Current & Forecasted Cases across the G8 Countries

Classical Hodgkin's Lymphoma - Market Opportunities and Sales Potential for Agents

Classical Hodgkin's Lymphoma - Patient-based Market Forecast to 2035

Classical Hodgkin's Lymphoma - Untapped Business Opportunities

Classical Hodgkin's Lymphoma - Product Positioning Vis-a-vis Competitors' Products

Classical Hodgkin's Lymphoma - KOLs Insight